April 14, 2021

Alicia Y. Zhou
Chief Science Officer
Color Health, Inc.
831 Mitten Road, Suite 100
Burlingame, CA 94010

Device: Color SARS-CoV-2 RT-LAMP Diagnostic Assay
EUA Number: EUA200539
Company: Color Health, Inc.
Indication: This test is authorized for the following indications for use:

- Qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swabs, oropharyngeal swabs, anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates, as well as bronchoalveolar lavage specimens collected from individuals suspected of COVID-19 by their healthcare provider.

- Qualitative detection of nucleic acid from SARS-CoV-2 in anterior nasal swabs collected from any individual, including from individuals without symptoms or other reasons to suspect COVID-19 infection.

- Qualitative detection of nucleic acid from SARS-CoV-2 in anterior nasal swab specimens that are collected using either the Color COVID-19 Self-Swab Collection Kit or the Color COVID-19 Self-Swab Collection Kit with Saline when used consistent with their authorizations.

Emergency use of this test is limited to the authorized laboratory.

Authorized Laboratory: Testing is limited to Color Health, Inc., located at 863 Mitten Road, Burlingame, CA 94010, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a., and meets requirements to perform high complexity tests.
Dear Alicia Y. Zhou:

On May 18, 2020, based on a request from Color Genomics, Inc., the Food and Drug Administration (FDA) determined that the Color SARS-CoV-2 LAMP Diagnostic Assay met the criteria for issuance under section 564(c) of the Act to be eligible for authorization under the March 31, 2020, Emergency Use Authorization (EUA) for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (High Complexity LDT Umbrella EUA) for the qualitative detection of nucleic acid from SARS-CoV-2 in respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3). As authorized under the High Complexity LDT umbrella EUA, testing was limited to the single laboratory that developed the authorized test and that is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a to perform high complexity tests pursuant to the Scope of Authorization and Conditions of Authorization of that EUA.1 On July 24, 2020, based on Color Genomics, Inc.’s request, FDA authorized use of the Color SARS-CoV-2 LAMP Diagnostic Assay with revisions incorporated.2 Based on Color Genomics, Inc.’s request, FDA also granted updates to the authorized labeling on August 28, 20203 and September 22, 2020.4 Based on Color Genomics, Inc.’s request, FDA reissued the July 24, 2020, letter in its entirety on November 2, 20205 and March 19, 2021,6 with the revisions

1 In this case, testing was limited to your laboratory located at 863 Mitten Road, Burlingame, CA 94010, which is certified under CLIA, 42 U.S.C. §263a., and meets requirements to perform high-complexity tests.

2 On July 24, 2020, because the requested revision to include self collection of nasal swab specimens was beyond the Scope of Authorization of the High Complexity LDT Umbrella EUA, FDA authorized use pursuant to Section 564 of the Act and the Scope of Authorization and Conditions of Authorization of the July 24, 2020, letter. Thus, the indication for the Color SARS-CoV-2 LAMP Diagnostic Assay was for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swabs, oropharyngeal swabs, anterior nares swabs, mid-turbinate nasal swabs, nasopharyngeal wash/aspirate or nasal aspirates, as well as bronchoalveolar lavage specimens collected from individuals suspected of COVID-19 by their healthcare provider. The test was also for use with nasal swab specimens that are self-collected at home or in a healthcare setting by individuals using an authorized home-collection kit specified in this EUA’s authorized labeling when determined to be appropriate by a healthcare provider. Testing was limited to Color Genomics, Inc., located at 863 Mitten Road, Burlingame, CA 94010, which is certified under CLIA, 42 U.S.C. §263a., and meets requirements to perform high-complexity tests.

3 On August 28, 2020, your request was granted to update the Instructions for Use (Laboratory SOP) of your product to; (1) remove the ORFlab primer set from the procedure and reporting algorithm (2) update the assay interpretation protocol, (3) remove redundant plate controls, (4) make minor changes to the SOP to provide clearer instructions to the assay operator, (5) change the name of the assay from “Color SARS-CoV-2 LAMP Diagnostic Assay” to “Color Genomics SARS-CoV-2 RT-LAMP Diagnostic Assay,” (6) update language in the “Medical Oversight and Process to be Used for Unmonitored Nasal Swab Collection” section of the EUA summary and (7) update the clinical evaluation section to accurately reflect the comparator that was used to evaluate the assay’s clinical performance.

4 On September 22, 2020, your request was granted via email to update the EUA Summary of your product to add the results of testing the FDA SARS-CoV-2 Reference Panel Testing.

5 On November 2, 2020 the revisions to the July 24, 2020, letter and authorized labeling included: (1) revising the name of the test from “Color Genomics SARS-CoV-2 RT-LAMP Diagnostic Assay” back to the original “Color SARS-CoV-2 LAMP Diagnostic Assay,” (2) removal of the Color COVID-19 Unmonitored Collection Kit as part of the Color SARS-CoV-2 LAMP Diagnostic Assay due to it being authorized on its own under the Color COVID-19 Self-Swab Collection Kit EUA, (3) updating the intended use to include use with dry nasal swab specimens that are self-collected unsupervised at home or in a healthcare setting by individuals using the Color COVID-19 Self-Swab Collection Kit when determined to be appropriate by a healthcare provider based on results of a COVID-19 medical questionnaire, (4) updates to the accessioning criteria to accurately reflect the dry swab stability claim of 56 hours, (5) revisions to the Healthcare Provider and Patient Fact Sheets to reflect the intended use updates and language more consistent with recent authorizations, and (6) revisions to the Conditions of Authorization as a result
incorporated.

On March 29, 2021, you\(^7\) requested to further amend this EUA. Based on this request, and having concluded that revising the March 19, 2021, EUA is appropriate to protect the public health or safety under section 564(g)(2)(C) of the Act (21 U.S.C. § 360bbb-3(g)(2)(C)), FDA is reissuing the March 19, 2021, letter in its entirety with the revisions incorporated.\(^8\) Pursuant to section 564 of the Act and the Scope of Authorization (Section II) and Conditions of Authorization (Section IV) of this reissued letter, your product\(^9\) is now authorized for use consistent with the indication described above.

On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act.\(^10\)

FDA considered the totality of scientific information available in authorizing the emergency use of your product for the indication above. A summary of the performance information FDA relied upon is contained in the EUA Summary (identified below).

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, as described in the Scope of Authorization (Section II), subject to the terms of this authorization.

---

\(^6\) On March 19, 2021, the revisions to the November 2, 2020, letter and authorized labeling included: (1) update the company name from “Color Genomics, Inc.” to “Color Health, Inc.” (2) revise the name of the device in the letter to “Color SARS-CoV-2 RT-LAMP Diagnostic Assay” and update the point of contact, (3) update the intended use to include testing of “anterior nasal swabs collected from any individual, including from individuals without symptoms or other reasons to suspect COVID-19 infection” and modify testing using dry anterior nasal swab specimens collection with “the Color COVID-19 Self-Swab Collection Kit, by individuals (18 years of age or older) suspected of COVID-19 or from individuals without symptoms or other reasons to suspect COVID-19 infection when determined to be appropriate by a healthcare provider,” (4) update the performance data to support testing of anterior nasal swabs collected from any individual, including from individuals without symptoms or other reasons to suspect COVID-19 infection, (5) revise the Healthcare Provider and Patient Fact Sheets to reflect the intended use updates and use language more consistent with recent authorizations, (6) revise the Conditions of Authorization as a result of the new intended use (including new I. and N.) and to use language consistent with recent authorizations, and (7) include additional limitation and information in the Healthcare Provider Fact Sheet regarding clinical evaluation of circulating variants, and additional limitation regarding asymptomatic testing.

\(^7\) For ease of reference, this EUA will use the term “you” and related terms to refer to Color Health, Inc.

\(^8\) The revisions to the March 19, 2021, letter and authorized labeling include: (1) addition of anterior nasal swab specimens collected using the Color COVID-19 Self-Swab Collection Kit with Saline and (2) modification of the Intended Use to be consistent with more recent authorizations.

\(^9\) For ease of reference, this letter will use the term “your product” to refer to the Color SARS-CoV-2 RT-LAMP Diagnostic Assay used for the indication identified above.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that:

1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus;

2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product; and

3. There is no adequate, approved, and available alternative to the emergency use of your product for diagnosing COVID-19.\(^\text{11}\)

II. Scope of Authorization

I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.

Authorized Product Details

Your product is a qualitative test for the detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swabs, oropharyngeal swabs, anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates, as well as bronchoalveolar lavage specimens collected from individuals suspected of COVID-19 by their healthcare provider, and anterior nasal swabs collected from any individual, including from individuals without symptoms or other reasons to suspect COVID-19 infection.

This test is also for use with anterior nasal swab specimens that are collected using either the Color COVID-19 Self-Swab Collection Kit or the Color COVID-19 Self-Swab Collection Kit with Saline when used consistent with their authorizations.

Testing is limited to Color Health, Inc., located at 863 Mitten Road, Burlingame, CA 94010, which is certified under CLIA and meets requirements to perform high complexity tests.

The SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical

\(^{11}\) No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the Act.
observations, patient history, and epidemiological information.

To use your product, SARS-CoV-2 nucleic acid is first extracted from upper respiratory and BAL specimens using a bead-based RNA extraction method. The extracted RNA is reverse-transcribed and amplified by loop-mediated isothermal amplification (LAMP). Targeted regions of viral or human RNA are amplified during isothermal incubation using a strand-displacing polymerase. The incorporation of dNTP's during amplification causes a pH change in the reaction which is visually detectable with pH-sensitive dyes and measured spectrophotometrically.

Your product requires the following control materials, or other authorized control materials (as may be requested under Condition K. below), that are to be run as outlined in the authorized labeling. All controls listed below must generate expected results in order for a test to be considered valid, as outlined in the authorized labeling:

- **Extraction Positive - control** (synthetic SARS-CoV-2 RNA and Human Total RNA) included in each extraction batch and carried through the full LAMP procedure; should exhibit positive signal for all three SARS-CoV-2 targets and the internal RNase P control. A lack of amplification would indicate that there was reagent or process failure during extraction or LAMP.

- **Extraction No Template Control (NTC)** - included in each extraction batch and carried through the full LAMP procedure; should not produce positive signal for any SARS-CoV-2 targets or the internal RNase P target. Amplification would indicate that there was contamination during extraction and/or with the LAMP reagents.

- **RNase P (internal control)** - should yield positive signal in every clinical specimen in order for the sample to be valid. Failure to detect RNase P in one specimen would invalidate that specific specimen and indicate extraction failure for that sample.

Your product also requires the use of additional authorized materials and authorized ancillary reagents that are not included with your product and are described in the authorized labeling.

Your product is authorized to be accompanied with the labeling submitted as part of the EUA request (listed below), and as described in the EUA summary (available at [https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas)), and the following fact sheets pertaining to the emergency use, which are required to be made available to healthcare providers and patients:

- **Fact Sheet for Healthcare Providers**: Color Health, Inc.- Color SARS-CoV-2 RT-LAMP Diagnostic Assay
- **Fact Sheet for Patients**: Color Health, Inc. - Color SARS-CoV-2 RT-LAMP Diagnostic Assay
The above described product, when accompanied by the EUA Summary, Fact Sheet for Healthcare Providers, Fact Sheet for Patients, and “Color SARS-CoV-2 RT-LAMP Diagnostic Assay (Rx) and Color SARS-CoV-2 RT-LAMP Diagnostic Assay DTC Standard Operating Procedure” (collectively referenced as “authorized labeling”), is authorized to be used by the authorized laboratory despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

I have concluded, pursuant to Section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of your product, when used consistent with the Scope of Authorization of this letter (Section II), outweigh the known and potential risks of your product.

I have concluded, pursuant to Section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that your product may be effective in diagnosing COVID-19, when used consistent with the Scope of Authorization of this letter (Section II), pursuant to Section 564(c)(2)(A) of the Act.

FDA has reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, and concludes that your product (as described in the Scope of Authorization of this letter (Section II)) meets the criteria set forth in Section 564(c) of the Act concerning safety and potential effectiveness.

The emergency use of your product under this EUA must be consistent with, and may not exceed the terms of this letter, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section IV). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the Act described above and the Secretary of HHS’s corresponding declaration under Section 564(b)(1) of the Act, your product is authorized for the indication above.

III. Waiver of Certain Requirements

I am waiving the following requirements for the product during the duration of this EUA:

- Current good manufacturing practice requirements, including the quality system requirements under 21 CFR Part 820 with respect to the design, manufacture, packaging, labeling, and storage, of your product.

IV. Conditions of Authorization

Pursuant to Section 564(e) of the Act, I am establishing the following conditions on this authorization:

Color Health, Inc. (You)

A. Your product must comply with the following labeling requirements under FDA regulations: the intended use statement (21 CFR 809.10(a)(2), (b)(2)); adequate directions for use (21 U.S.C. 352(f)), (21 CFR 809.10(b)(5), (7), and (8)); appropriate
limitations on the use of the device including information required under 21 CFR 809.10(a)(4); and any available information regarding performance of the device, including requirements under 21 CFR 809.10(b)(12).

B. You must inform relevant public health authorities of this EUA, including the terms and conditions herein, and any updates made to your authorized product and/or authorized labeling.

C. You must notify the relevant public health authorities of your intent to run your product.

D. You must have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate. You must also have a process in place for reporting test results via the agreed upon process as authorized by the EUA for the Color COVID-19 Self-Swab Collection Kit and the Color COVID-19 Self-Swab Collection Kit with Saline.

E. You must include with test result reports, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.

F. You must make available on your website(s), if applicable, the Fact Sheet for Healthcare Providers and Fact Sheet for Patients.

G. You are authorized to make available additional information relating to the emergency use of your product that is consistent with, and does not exceed, the terms of this letter of authorization.

H. You must use your product as outlined in the authorized labeling. Deviations from the authorized labeling, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and/or authorized materials required to use your product are not permitted.

I. When testing anterior nasal swab specimens collected using the Color COVID-19 Self-Swab Collection Kit or the Color COVID-19 Self-Swab Collection Kit with Saline authorized for use with your product, you must follow any specimen accessioning protocol provided with the collection kits when accepting specimens for testing.

J. You must collect information on the performance of your product. You will report to Division of Microbiology (DMD)/Office of Health Technology 7 (OHT7)-Office of In Vitro Diagnostics and Radiological Health (OIR)/Office of Product Evaluation and Quality (OPEQ)/Center for Devices and Radiological Health (CDRH) (via email: CDRH-EUA-Reporting@fda.hhs.gov) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of your product of which you become aware.
K. You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling. Any request for changes to this EUA should be submitted to the DMD/OHT7-OIR/OPEQ/CDRH and require appropriate authorization from FDA prior to implementation.

L. You must evaluate the analytical limit of detection and assess traceability\(^\text{12}\) of your product with any FDA-recommended reference material(s), if requested by FDA. After submission to and review of and concurrence with the data, FDA will update the EUA Summary to reflect the additional testing.

M. You must have a process in place to track adverse events, including any occurrence of false results with your product, including with the Color COVID-19 Self-Swab Collection Kit, in accordance with 21 CFR Part 803. Serious adverse events, especially unexpected biosafety concerns, must immediately be reported to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUAReporting@fda.hhs.gov).

N. You must submit to FDA a summary report within 30 calendar days of authorization summarizing the results of any testing performed using anterior nasal swab specimens collected with the Color COVID-19 Self-Swab Collection Kit and the Color COVID-19 Self-Swab Collection Kit with Saline during that timeframe, including how many kits were activated via the online portal, purchased from an authorized distributor for home collection, or collected at a community-based site or distribution center, how many kits were processed, how many specimens were rejected during accessioning and the reasons for rejection, and the positivity rate.

O. All laboratory personnel using your product must be appropriately trained in molecular techniques and use appropriate laboratory and personal protective equipment when handling this product and use your product in accordance with the authorized test procedure.

P. You must ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

**Conditions Related to Printed Materials, Advertising and Promotion**

Q. All descriptive printed matter, advertising, and promotional materials relating to the use of your product shall be consistent with the authorized labeling, as well as the terms set forth in this EUA and the applicable requirements set forth in section 502(a), (q)(1), and (r) of the Act and FDA implementing regulations.

R. No descriptive printed matter, advertising, or promotional materials relating to the use of your product may represent or suggest that this test is safe or effective for the detection of

\(^{12}\) Traceability refers to tracing analytical sensitivity/reactivity back to an FDA-recommended reference material. FDA may request, for example, that you perform this study if we receive reports of adverse events concerning your product.
SARS-CoV-2.

S. All descriptive printed matter, advertising, and promotional materials relating to the use of your product shall clearly and conspicuously state that:

- This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories;
- This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The emergency use of your product as described in this letter of authorization must comply with the conditions and all other terms of this authorization.

V. Duration of Authorization

This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act.

Sincerely,

____________________________
RADM Denise M. Hinton
Chief Scientist
Food and Drug Administration

Enclosure